Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-Label Ibrutinib in Relapsed/Refractory Marginal Zone Lymphoma
2013-003561-34Phase 2Completed
- Sponsor
- Pharmacyclics
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibrutinib in marginal zone B-cell lymphoma (MZL) and non-Hodgkin lymphoma (NHL), sponsored by Pharmacyclics. Primary endpoint: Overall response rate. Started Nov 2013; status: completed.
02
Drugs
ibrutinib
03
Conditions
marginal zone B-cell lymphoma (MZL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2013-003561-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003561-34.